NFKB1 and cataract: The current DMD treatment, corticosteroid therapy, reduces inflammation, but comes with many unwanted side effects, including cataracts, growth impairment and reduction in bone density.39 An anti-NF-κB therapy can only be temporary, at best, given the ubiquitous nature of this transcription factor, especially in immunity.